Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.Edoardo Francini, Daniel Yick Chin Heng, Nimira Alimohamed et al.|Journal of Clinical Oncology|2020Cited by 1
Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.Edoardo Francini, Daniel Yick Chin Heng, Francesca Montagnani et al.|Journal of Clinical Oncology|2019Cited by 0